On the other hand, tumours, such as squamous cell, prostate, and colorectal carcinomas in which FGFR2b activation has not been documented, appear to retain their sensitivity to cytoablative treatments in the presence of KGF [108–111]. The gene discussed is FGF7; the disease is neoplasm.